Cases & Deals

  • Home
  • Practices
  • OticPharma licenses novel treatment for ear infections from Otodyne

Share

OticPharma licenses novel treatment for ear infections from Otodyne

November 2015

Client(s) OticPharma, Inc.

Jones Day represented OticPharma, Inc. in the acquisition of worldwide rights of Otodyne and its affiliate SDRI to OTO-101, a novel treatment for otitis media based upon spraying a surfactant composition into the nose. OticPharma will take control of the IND for the treatment and continue to develop, seek regulatory approval for, and commercialize the treatment method.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.